US2018147245A1PendingUtilityA1
Selective cell targeting using adenovirus and chemical dimers
Assignee: SALK INST FOR BIOLOGICAL STUDIPriority: Mar 13, 2012Filed: Jan 23, 2018Published: May 31, 2018
Est. expiryMar 13, 2032(~5.6 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 35/00C12N 2710/10345A61K 35/761C07K 2319/20C12N 15/86C12N 2710/10034C12N 7/00C12N 2710/10052C12N 15/113A61K 48/00
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Compositions and methods for retargeting adenovirus to a cell using chemical dimers are described. In particular, a recombinant adenovirus comprising a nucleic acid comprising a capsid-dimerizing agent binder conjugate and a ligand-dimerizing agent binder conjugate is provided.
Claims
exact text as granted — not AI-modified1 . A recombinant nucleic acid encoding a capsid-dimerizing agent binder conjugate and a ligand-dimerizing agent binder conjugate, wherein the capsid-dimerizing agent binder conjugate comprises an adenoviral fiber protein and a FRB protein inserted into the H1 loop of the adenoviral fiber protein, and the ligand-dimerizing agent binder conjugate comprises a ligand and a FKBP protein.
2 . The recombinant nucleic acid of claim 1 , wherein the ligand is capable of binding a tumor cell.
3 . The recombinant nucleic acid of claim 2 , wherein the ligand is an antibody.
4 . The recombinant nucleic acid of claim 3 , wherein the antibody is a single domain antibody.
5 . The recombinant nucleic acid of claim 1 , wherein the FRB protein is 90 amino acids in length.
6 . The recombinant nucleic acid of claim 1 , wherein the FRB protein comprises a wild-type mTOR FRB domain.
7 . The recombinant nucleic acid of claim 1 , wherein the FRB protein is encoded by the nucleotide sequence of SEQ ID NO: 69.
8 . The recombinant nucleic acid of claim 1 , wherein the FRB protein comprises a mutant mTOR FRB domain.
9 . The recombinant nucleic acid of claim 8 , comprising SEQ ID NO: 110.
10 . The recombinant nucleic acid of claim 1 , wherein the FKBP protein is a human FKBP protein.
11 . The recombinant nucleic acid of claim 10 , wherein the human FKBP protein is FKBP12.
12 . A recombinant adenovirus comprising the recombinant nucleic acid of claim 1 .
13 . A recombinant adenovirus comprising a capsid-dimerizing agent binder conjugate, wherein the capsid-dimerizing agent binder conjugate comprises an adenoviral fiber protein and a FRB protein inserted into the H1 loop of the adenoviral fiber protein.
14 . The recombinant adenovirus of claim 13 , wherein the capsid-dimerizing agent binder conjugate is bound to a dimerizing agent.
15 . The recombinant adenovirus of claim 14 , wherein the dimerizing agent is further bound to a ligand-dimerizing agent binder conjugate.
16 . The recombinant adenovirus of claim 14 , wherein the dimerizing agent is rapamycin or a rapalog.
17 . The recombinant adenovirus of claim 13 , wherein the FRB protein is 90 amino acids in length.
18 . The recombinant adenovirus of claim 13 , wherein the FRB protein comprises a wild-type mTOR FRB domain.
19 . The recombinant adenovirus of claim 18 , wherein the FRB protein is encoded by the nucleotide sequence of SEQ ID NO: 69.
20 . The recombinant adenovirus of claim 13 , wherein the FRB protein comprises a mutant mTOR FRB domain.Join the waitlist — get patent alerts
Track US2018147245A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.